Novo Nordisk continues to limit starter doses of popular weight-loss drug Wegovy in the US; veterans and survivors received an error message when submitting PACT Act claims shortly before the deadline; insurance companies are failing to inform patients of their eligibility for free preventative services.
Novo Nordisk Continues to Limit Supply of Weight-Loss Drug Wegovy
Novo Nordisk announced Thursday that it will continue to restrict starter doses of popular weight-loss drug Wegovy in the United States most likely into 2024 as it struggles to keep up with the soaring demand, according to Reuters. Wegovy is a weekly injection that, paired with diet and exercise changes, could help patients lose 15% of their weight. This announcement comes after the success of the company’s efforts in May to halve its supply of starter doses in the US market for several months to ensure the availability of supplies for existing patients. The limits on Wegovy may cause Novo Nordisk to lose out on market share to competitors working on similar weight-loss therapies. On the other hand, despite these supply limits, the company raised its full-year profit and sales forecast for a second time this year.
Veterans Shutout Before PACT Act Deadline
An “extremely high volume” of PACT Act claims overwhelmed the Department of Veteran Affairs website on Tuesday, preventing veterans and survivors from submitting claims and notices of intention to file claims as the deadline for backdated payments approached, according to Military.com. About 18% of veterans and survivors received error messages while trying to submit by Wednesday’s deadline to receive retroactive disability payments dated to when President Joe Biden signed the PACT Act into law on August 10, 2022. Veterans Affairs said that it is working to resolve the site issues and that, despite the system overload, it will honor the submissions affected. The PACT Act expanded health care and disability to those exposed to environmental pollution, like burn pits, while serving. Veterans who develop a related illness, or their survivors, can file a claim at any time, along with those already affected, to receive retroactive benefits back to August 10, 2022.
Patients Potentially Missing Out on Free Cancer Screenings, Vaccinations
A new report from consumer representatives to the National Association of Insurance Commissioners revealed that health insurers are failing to inform patients about free preventive services they are entitled to, according to Axios. HHS reported last year that this free coverage includes cancer screenings and vaccinations. These consumer representatives examined information from 6 plans in 6 states about coverage of smoking cessation, HIV prevention medication, colorectal cancer screening, and postpartum depression screening. They found that consumer documents often had missing or inconsistent information about preventive services coverage. The representatives recommended that state regulators review claims data more closely to ensure patients are not getting improperly billed and to interfere if that is the case.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More